Tyra Biosciences, Inc.

NASDAQ:TYRA

Biotechnology

Healthcare
$19.61 -2.48%

-$0.72 today

Market cap
$1.35B
Beta
0.75
P/E (TTM)
-13.4
EPS (TTM)
-$2.12
52W Low $8.98High $40.65

Volume 0.47M

Average 0.96M

TYRA Total Current Liabilities

All obligations due within one year.

Tyra Biosciences, Inc.NASDAQ: TYRA

Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Total current liabilities rises 35.2% from a year ago

Total current liabilities stood at $19.26M at the end of Q1 FY2026, up 35.2% from a year earlier and up 6.4% from the prior quarter. Over 3 fiscal years it compounded at +47.0% a year.

Context

  • Total current liabilities amounted to 4.7% of total assets at the end of Q1 FY2026, up 0.5 pp from a year earlier.
  • Total current liabilities increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total current liabilities keeps rising in the next quarterly balance sheet after a +35.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$19.26M+6.4% QoQ
Last fiscal yearDec 2025
$18.09M+24.0% YoY
Year agoMar 2025
$14.25M+35.2% since
Total Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+35.2%——
1 year+24.0%——
3-year CAGR+47.0%——
5-year CAGR——
10-year CAGR——

Total Current Liabilities history

USD · from the balance sheet

Latest · FY2025
18.09M USD
Year-over-year change
+24.0%
4-year CAGR
+49.6%

Total Current Liabilities vs competitors

How TYRA compares with its peers on the latest reported figures

  • TYRA's Mar 2026 total current liabilities of $19.26M is the 10th highest of the 11 companies compared; the peer median is $61.66M.
  • Its year-over-year change of +35.2% is the 6th highest of 11, against a peer median of +51.9%.
  • Total current liabilities amounts to 4.7% of total assets for TYRA, versus a peer median of 10.2%.
TYRA Competitors Peer median
Total Current Liabilities for TYRA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
KURAKura Oncology, Inc.Mar 2026$101.5M +13.1%+69.4%15.6%
MGNXMacroGenics, Inc.Mar 2026$95.94M +73.0%-3.9%44.0%
NUVBNuvation Bio Inc.Jun 2026$86.76M +30.7%+84.2%11.7%
VSTMVerastem, Inc.Mar 2026$66.85M +87.7%+49.4%29.3%
FHTXFoghorn Therapeutics Inc.Mar 2026$64.4M -9.7%+2.7%29.0%
JANXJanux Therapeutics, Inc.Mar 2026$58.92M +236.6%+14.8%5.7%
BCAXBicara Therapeutics Inc. Common StockMar 2026$39.34M +105.8%+6.6%7.1%
CGEMCullinan Therapeutics, Inc.Mar 2026$35.15M +28.5%+18.8%8.7%
AVBPArriVent BioPharma, Inc. Common StockMar 2026$25M +93.0%+45.9%7.2%
TYRATyra Biosciences, Inc.Mar 2026$19.26M +35.2%+47.0%4.7%
ORICORIC Pharmaceuticals, Inc.Mar 2026$17.77M +0.9%+9.9%4.1%
Peer median (excluding TYRA) $61.66M+51.9%+16.8%10.2%

Competitors are the stored peer set for TYRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents302.18M251.21M58.01M91.97M77.39M
Short-term Investments00145.46M249.48M178.62M
Net Receivables0002M0
Inventory00000
Other Current Assets06.08M8.2M4.02M9.45M
Total Current Assets304.06M257.29M211.67M347.46M265.45M
Property, Plant & Equipment (Net)2.09M3.54M8.15M7.72M6.89M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets555K5.35M6.03M8.38M10.27M
Total Non-current Assets2.64M8.89M14.19M16.1M17.16M
Total Assets306.7M266.18M225.86M363.56M282.61M
Account Payables599K1.15M4.66M590K1.18M
Short-term Debt000412K472K
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities005.27M7.14M10.91M
Total Current Liabilities3.62M5.7M15.33M14.59M18.09M
Long-term Debt00005.34M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities367K169K46K3K0
Total Non-current Liabilities1.35M2.65M6.26M5.81M5.34M
Total Liabilities4.96M8.35M21.6M20.41M23.43M
Common Stock4K4K4K5K5K
Retained Earnings(40.37M)(95.7M)(164.83M)(251.31M)(371.26M)
Accumulated OCI00381K770K393K
Other Stockholders Equity00000
Minority Interest00000
Total Equity301.74M257.83M204.26M343.15M259.18M
Total Debt1.18M2.62M6.5M6.22M5.81M
Net Debt(301M)(248.59M)(51.51M)(85.74M)(71.58M)

Tyra Biosciences, Inc.

NASDAQ:TYRA

Intrinsic Alpha fair value

Locked

Current Price

$19.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.